Peptide-based diagnostic and therapeutic agents: Where we are and where we are heading?

PARLAK KHALİLY M., SOYDAN M.

CHEMICAL BIOLOGY & DRUG DESIGN, vol.101, no.3, pp.772-793, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 101 Issue: 3
  • Publication Date: 2023
  • Doi Number: 10.1111/cbdd.14180
  • Journal Name: CHEMICAL BIOLOGY & DRUG DESIGN
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.772-793
  • Keywords: peptide probes, peptide therapeutics, radiolabeled peptides, targeting, POSITRON-EMISSION-TOMOGRAPHY, IRON-OXIDE NANOPARTICLES, IN-VIVO EVALUATION, INTEGRIN ALPHA(V)BETA(3) EXPRESSION, STIMULATING HORMONE ANALOG, CELL-PENETRATING PEPTIDES, RADIOLABELED RGD PEPTIDES, CONJUGATED QUANTUM DOTS, PROSTATE-CANCER, IMAGING PROBES
  • Middle East Technical University Affiliated: Yes

Abstract

Peptides are increasingly present in all branches of medicine as innovative drugs, imaging agents, theragnostic, and constituent moieties of other sophisticated drugs such as peptide-drug conjugates. Due to new developments in chemical synthesis strategies, computational biology, recombinant technology, and chemical biology, peptide drug development has made a great progress in the last decade. Numerous natural peptides and peptide mimics have been obtained and studied, covering multiple therapeutic areas. Even though peptides have been investigated across the wide therapeutic spectrum, oncology, metabolism, and endocrinology are the most frequent medical indications of them. This review summarizes the current use of and the emerging new opportunities of peptides for diagnosis and treatment of various diseases.